Clinical Trials Sponsored by Y-mAbs Therapeutics, Inc

Total 27 results

Y-mAbs Therapeutics

Withdrawn

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Solid Tumor, Adult | Leptomeningeal Metastasis

United States, United Kingdom
Y-mAbs Therapeutics

Not yet recruiting

Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma

United States
Y-mAbs Therapeutics

Recruiting

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Sarcoma | SCLC | Malignant Melanoma

United States
Y-mAbs Therapeutics

Recruiting

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Neuroblastoma

Spain, Denmark, United States, Italy, United Kingdom, Germany, Hong Kong, Canada, France
Y-mAbs Therapeutics

Terminated

Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma

Neuroblastoma Recurrent

Korea, Republic of, Hong Kong
Y-mAbs Therapeutics

Terminated

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

Medulloblastoma, Childhood

United States, Spain, United Kingdom, Denmark, Netherlands
Y-mAbs Therapeutics

Terminated

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Neuroblastoma | Leptomeningeal Metastases | CNS Metastases

United States, Denmark, Japan, Spain
Y-mAbs Therapeutics

Terminated

Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

Peritoneal Cancer

United States
Y-mAbs Therapeutics

Terminated

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Osteosarcoma | Neuroblastoma | Other Solid Tumor Cancers

United States
Y-mAbs Therapeutics

Terminated

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

SCLC

United States
Y-mAbs Therapeutics

Withdrawn

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Neuroblastoma

Korea, Republic of, Singapore, Hong Kong, Russian Federation
Y-mAbs Therapeutics
Children's Oncology Group

Terminated

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

AML, Childhood

United States
Y-mAbs Therapeutics
Invicro; Labcorp Corporation of America Holdings, Inc

Withdrawn

131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

DIPG
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Recruiting

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

Peritoneal Carcinoma | Peritoneal Cancer | Desmoplastic Small Round Cell Tumor

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Available

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Central Nervous System/Leptomeningeal Neoplasms

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Melanoma | Sarcoma | Neuroblastoma

United States
Y-mAbs Therapeutics
Memorial Sloan Kettering Cancer Center

Terminated

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Sarcoma | Brain and Central Nervous System Tumors | Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | High-Risk

United States
Y-mAbs Therapeutics
Memorial Sloan Kettering Cancer Center

Completed

Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Brain Cancer | Brain Stem Glioma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Neuroblastoma (NB)

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics; Band of Parents

Completed

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Neuroblastoma

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; Y-mAbs...

Active, not recruiting

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Recurrent Ependymoma | Recurrent Medulloblastoma

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Children's Hospital Los Angeles; Y-mAbs Therapeutics

Active, not recruiting

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Recurrent Osteosarcoma

United States
Mads Peter Godtfeldt Stemmerik
Edgewise Therapeutics, Inc.

Completed

Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases

Becker Muscular Dystrophy | McArdle Disease | Limb-Girdle Muscular Dystrophy Type 2

Denmark

Clinical Trials Sponsored by Y-mAbs Therapeutics, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations